The respective commercial launches of Vivus' (VVUS - Get Report) Qsymia and Arena Pharmaceuticals' (ARNA - Get Report) Belviq have underwhelmed this year, leading to a steep drop in their stock prices.
So, it seems as if Orexigen has actually benefitted from the protracted FDA review and delayed commercial launch of its obesity pill Contrave. On Monday, Contrave passed a key heart-safety test, which should lead to the drug's approval next June.Will Orexigen and its marketing partner Takeda succeed where rivals have (so far) failed? Takeda has a lot of metabolic drug marketing experience -- Actos is a blockbuster diabetes drug -- which should proven beneficial with the Contrave launch. Orexigen's enterprise value is still significantly lower than Arena and Vivus.
OREX Enterprise Value data by YCharts
-- Reported by Adam Feuerstein in Boston. Follow Adam Feuerstein on Twitter.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts